FDA Approves Once-Weekly Growth Hormone for Turner Syndrome in Children 2.5+
The Food and Drug Administration approved the once-weekly long-acting growth hormone somapacitan-beco on Friday for treating children aged 2.5 years and older with growth failure associated with Turner syndrome, according to Novo Nordisk.
- Somapacitan-beco (Sogroya) is now approved as a once-weekly alternative to daily injections for pediatric patients with Turner syndrome aged 2.5 years and older.
- Approval is based on the Phase 3 REAL8 trial, which showed height velocity comparable to daily somatropin over 52 weeks.
- The treatment aims to reduce injection frequency, providing 313 injection-free days each year compared to daily therapy regimens.
Turner syndrome is a chromosomal condition occurring in about 1 in 2,000 female newborns where girls have a missing or altered X chromosome, medscape.com reported. This condition commonly leads to short stature alongside problems affecting the heart, kidneys, and reproductive system.
“For children with Turner Syndrome, growth hormone treatment can be part of everyday life for years. How they experience that treatment matters,” Colleen Silk, Group Vice President, Rare Disease, Novo, said in a news release reported by novonordisk.mediaroom.com.
The newly approved indication is based on the multicenter, randomized, open-label, active-comparator, Phase 3 REAL8 study, empr.com reported. The trial enrolled 105 children aged 2.5 to 10 years who had Turner syndrome and short stature associated with being born small for gestational age with no catch-up growth by 2 years.

Patients were randomized 2:1 to receive either 0.24 mg/kg/week of somapacitan-beco or once-daily somatropin at 0.05 mg/kg/day, a dose lower than the maximum 0.067 mg/kg/day dose approved for pediatric patients with Turner syndrome in the United States, contemporarypediatrics.com reported.
Somapacitan-Beco Shows 8.9 Cm/Year Growth Velocity
| Treatment Group | Patient Count (n) | Mean Annualized Height Velocity | Height Standard Deviation Score Change |
|---|---|---|---|
| Somapacitan-beco (0.24 mg/kg/wk) | 68 | 8.9 cm/year | 0.77 |
| Somatropin (0.05 mg/kg/day) | 37 | 9.7 cm/year | 0.86 |
At the 52-week mark, the primary endpoint of mean annualized height velocity was 8.9 cm/year with once-weekly somapacitan-beco compared to 9.7 cm/year with daily somatropin, yielding an estimated nonsignificant treatment difference of -0.8 cm/year, medscape.com reported. The annualized height standard deviation score from baseline to week 52 was 0.77 for the weekly treatment group and 0.86 for the daily treatment group.
The injection is supplied in prefilled pens at doses of 5 mg, 1.5 mL, 10 mg, 1.5 mL, or 15 mg, 1.5 mL, according to the Sogroya package insert. Adverse reactions occurring in 10% or more of participants treated with somapacitan-beco included respiratory tract infection, nasopharyngitis, ear infection, pyrexia, diarrhea, vomiting, and injection-site reaction, medscape.com reported. Trial participants are continuing in a 2-year safety extension phase.
Weekly Somapacitan-Beco Reduces Injection Burden
Daily growth hormone therapy works well, but staying consistent with treatment over time can be difficult, especially in conditions like Turner syndrome where families may struggle with managing multiple comorbidities and medications, Dr. Aristides Maniatis, Founder, Rocky Mountain Endocrinology and an investigator in the REAL8 trial, told empr.com.
“By offering a once-weekly treatment option, Sogroya provides 313 injection-free days each year,” said Maniatis, as reported by novonordisk.mediaroom.com. “This weekly alternative to daily therapy may help make the growth hormone routine simpler to fit into the lives of children and their caregivers.”
Trial participants are continuing in a 2-year safety extension phase, medscape.com reported on November 20, 2026.
The Danish multinational pharmaceutical company Novo Nordisk traces its origins to the 1920s with the founding of Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium, which merged in 1989 to form the current corporation. By 2023, the company employed approximately 69,500 people across 80 countries and its market capitalization exceeded the gross domestic product of Denmark, making it the highest valued company in Europe.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.